BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1513 related articles for article (PubMed ID: 25307619)

  • 1. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
    BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
    Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
    J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?
    Castellucci P; Fuccio C; Rubello D; Schiavina R; Santi I; Nanni C; Allegri V; Montini GC; Ambrosini V; Boschi S; Martorana G; Marzola MC; Fanti S
    Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):55-63. PubMed ID: 20848281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
    Castellucci P; Ceci F; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Pettinato C; Celli M; Lodi F; Fanti S
    J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution.
    Marzola MC; Chondrogiannis S; Ferretti A; Grassetto G; Rampin L; Massaro A; Castellucci P; Picchio M; Al-Nahhas A; Colletti PM; Marcolongo A; Rubello D
    Clin Nucl Med; 2013 Jan; 38(1):e26-32. PubMed ID: 23242060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic performance of
    Samper Ots P; Luis Cardo A; Vallejo Ocaña C; Cabeza Rodríguez MA; Glaria Enríquez LA; Couselo Paniagua ML; Olivera Vegas J
    Clin Transl Oncol; 2019 Jun; 21(6):766-773. PubMed ID: 30448957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of PET-CT with
    Puche-Sanz I; Triviño-Ibáñez E; Vázquez-Alonso F; Llamas-Elvira JM; Cózar-Olmo JM; Rodríguez-Fernández A
    Actas Urol Esp; 2017 Sep; 41(7):437-444. PubMed ID: 28389027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significant increase in detection of prostate cancer recurrence following radical prostatectomy with an early imaging acquisition protocol with ¹⁸F-fluorocholine positron emission tomography/computed tomography.
    Simone G; Di Pierro GB; Papalia R; Sciuto R; Rea S; Ferriero M; Guaglianone S; Maini CL; Gallucci M
    World J Urol; 2015 Oct; 33(10):1511-8. PubMed ID: 25577130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy.
    Giovacchini G; Picchio M; Scattoni V; Garcia Parra R; Briganti A; Gianolli L; Montorsi F; Messa C
    Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1106-16. PubMed ID: 20306038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml.
    Evangelista L; Cuppari L; Guttilla A; Gardi M; Agostini A; Ruggera L; Basso U; Saladini G
    Nucl Med Commun; 2018 Mar; 39(3):260-267. PubMed ID: 29381584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy.
    Giovacchini G; Picchio M; Parra RG; Briganti A; Gianolli L; Montorsi F; Messa C
    Clin Nucl Med; 2012 Apr; 37(4):325-31. PubMed ID: 22391699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy.
    Ceci F; Castellucci P; Mamede M; Schiavina R; Rubello D; Fuccio C; Ambrosini V; Boschi S; Martorana G; Fanti S
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(2):149-55. PubMed ID: 23151910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
    Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
    J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET/CT with (18)F-choline after radical prostatectomy in patients with PSA ≤2 ng/ml. Can PSA velocity and PSA doubling time help in patient selection?
    Chiaravalloti A; Di Biagio D; Tavolozza M; Calabria F; Schillaci O
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1418-24. PubMed ID: 26791373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer: experience with 1,000 patients.
    Cimitan M; Evangelista L; Hodolič M; Mariani G; Baseric T; Bodanza V; Saladini G; Volterrani D; Cervino AR; Gregianin M; Puccini G; Guidoccio F; Fettich J; Borsatti E
    J Nucl Med; 2015 Feb; 56(2):209-15. PubMed ID: 25552670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study of the utility of choline PET-CT in prostate cancer biochemical relapse following radical prostatectomy.
    Tan H; Joseph D; Loh NK; McCarthy M; Leong E; Siew T; Segard T; Morandeau L; Trevenen M; Francis RJ
    J Med Imaging Radiat Oncol; 2016 Jun; 60(3):374-81. PubMed ID: 27094471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (18)F-choline PET/CT for early detection of metastases in biochemical recurrence following radical prostatectomy.
    Kjölhede H; Ahlgren G; Almquist H; Liedberg F; Lyttkens K; Ohlsson T; Bratt O
    World J Urol; 2015 Nov; 33(11):1749-52. PubMed ID: 25824540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy.
    Giovacchini G; Picchio M; Coradeschi E; Bettinardi V; Gianolli L; Scattoni V; Cozzarini C; Di Muzio N; Rigatti P; Fazio F; Messa C
    Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):301-9. PubMed ID: 19756592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of tumor recurrences after radical prostatectomy using 18F-Choline PET/CT and 3T multiparametric MRI without endorectal coil: a single center experience.
    Couñago F; Recio M; Maldonado A; Del Cerro E; Díaz-Gavela AA; Thuissard IJ; Sanz-Rosa D; Marcos FJ; Olaciregui K; Mateo M; Cerezo L
    Cancer Imaging; 2016 Dec; 16(1):42. PubMed ID: 27927229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 76.